{"filing":{"accession_number":"0001104659-26-073787","cik":"0001567892","ticker":null,"company_name":"Keenova Therapeutics plc","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"tm2617927d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1567892/000110465926073787/tm2617927d1_8k.htm"},"events":[{"id":10912,"run_id":9572,"accession_number":"0001104659-26-073787","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Keenova entered into a purchase agreement to sell its Percocet and Endocet businesses to Par Health, Inc. for approximately $250 million in upfront and earnout consideration. This is a material disposition of business units that will result in Keenova exiting the opioid product market entirely, representing a significant strategic and financial transaction that would affect a reasonable investor's assessment of the company.","company_name":"Keenova Therapeutics plc","ticker":null,"filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7349,"accession_number":"0001104659-26-073787","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Keenova entered into a purchase agreement to sell its Percocet and Endocet businesses to Par Health, Inc. for approximately $250 million in upfront and earnout consideration. This is a material disposition of business units that will result in Keenova exiting the opioid product market entirely, representing a significant strategic and financial transaction that would affect a reasonable investor's assessment of the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:02:16.560750+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7349,"accession_number":"0001104659-26-073787","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Keenova entered into a purchase agreement to sell its Percocet and Endocet businesses to Par Health, Inc. for approximately $250 million in upfront and earnout consideration. This is a material disposition of business units that will result in Keenova exiting the opioid product market entirely, representing a significant strategic and financial transaction that would affect a reasonable investor's assessment of the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:02:16.560750+00:00","company_name":"Keenova Therapeutics plc","ticker":null,"filing_date":"2026-06-15"}]}